RE: Futura (fut)27 Sep 2023 16:46
Post period highlights
· USA: Futura entered into a ground-breaking licensing agreement in July 2023 with Haleon, the world leading consumer healthcare company, for exclusive rights to commercialise MED3000 in the USA.
o Under the agreement, Futura received an upfront payment of $4 million and will receive royalty payments on all sales, and potentially up to a further $45 million in commercial and performance driven sales milestone payments.
· Middle East: MED3000 marketing authorisation granted in six Middle Eastern countries.
o Marketing authorisation under the Eroxon® brand name recently granted in the Kingdom of Saudi Arabia, one of the top ten ED markets in the world by value.
o Initial Middle East launch planned in Q4 2023.